seminoma (Cancer)
Information
- Disease name
- seminoma
- Disease ID
- DOID:4440
- Description
- "A germinoma that has_material_basis_in cells that make sperm and eggs." [url:http\://www.cancer.gov/dictionary?CdrID=46577]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| KIT | 4 | 54,657,913 | 54,740,770 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03158064 | Active, not recruiting | Phase 2 | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | May 15, 2017 | November 2024 |
| NCT02834013 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | January 30, 2017 | May 1, 2026 |
| NCT03937843 | Active, not recruiting | Phase 2 | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma | July 29, 2019 | December 31, 2046 |
| NCT01593241 | Active, not recruiting | Phase 2 | Therapy De-escalation in Seminoma Stage IIA/B | June 15, 2012 | September 2038 |
| NCT02375204 | Active, not recruiting | Phase 3 | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors | August 5, 2015 | June 2024 |
| NCT00705094 | Completed | Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients | September 2008 | July 2012 | |
| NCT05142982 | Not yet recruiting | N/A | Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma | December 15, 2021 | December 15, 2029 |
| NCT06133543 | Recruiting | N/A | Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer | September 6, 2023 | October 31, 2026 |
| NCT06144736 | Recruiting | Phase 2 | PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND | August 28, 2023 | August 31, 2029 |
| NCT06309745 | Recruiting | THERApy De-escalation for TESTicular Cancer | January 25, 2024 | December 2027 | |
| NCT01887340 | Recruiting | Phase 2 | Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma | June 2013 | June 2026 |
| NCT02341989 | Recruiting | Phase 3 | Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer | April 8, 2015 | December 2035 |
| NCT04435756 | Recruiting | A Study of miRNA 371 in Patients With Germ Cell Tumors | July 28, 2020 | October 1, 2026 | |
| NCT04876456 | Recruiting | Phase 2 | A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | June 10, 2021 | December 2025 |
| NCT04914026 | Recruiting | MicroRNA as Markers in Testicular Cancer | December 31, 2016 | December 31, 2026 | |
| NCT05529251 | Recruiting | Phase 2 | De-escalation Study for Stage IIa/IIb < 3 cm Seminoma | September 6, 2022 | September 6, 2030 |
- Disase is a (Disease Ontology)
- DOID:2994
- Cross Reference ID (Disease Ontology)
- ICDO:9061/3
- Cross Reference ID (Disease Ontology)
- MESH:D018239
- Cross Reference ID (Disease Ontology)
- NCI:C9309
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:443675005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0036631
- Exact Synonym (Disease Ontology)
- Seminoma, Pure
- MeSH unique ID (MeSH (Medical Subject Headings))
- D018239